Purple Biotech Ltd., a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently announced additional positive interim results from its randomized Phase 2 study of CM24. The study evaluates the combination of CM24 with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. These results have shed light on the potential role of serum MPO as a predictive biomarker for improved overall survival in the treated patient population.
The Study
The Phase 2 study (NCT 04731467) conducted by Purple Biotech is an open-label, multicenter trial comparing the combination therapy of CM24, nivolumab, and standard treatments (Nal-IRI/5FU/LV) with standard treatments alone as the control group. The study aims to assess the efficacy and safety of this novel combination in patients with second-line metastatic PDAC.
Additional Interim Data Findings
Purple Biotech’s interim data reveals that patients receiving CM24 in combination with nivolumab and standard treatments showed promising results in terms of overall survival. Notably, the study suggests that serum MPO (myeloperoxidase) levels could serve as a valuable predictive biomarker for survival benefits. This finding raises the potential for personalized treatment plans in patients with metastatic PDAC, allowing for better prognostication and improved patient outcomes.
Virtual KOL Event
In light of the positive interim results, Purple Biotech has scheduled a virtual KOL (Key Opinion Leader) event to discuss the findings in greater detail. The event, scheduled for Thursday, July 11, 2024, at 10:30 AM ET, aims to provide further insight into the study’s implications and their significance for future therapeutic approaches.
Impact on the Company
The additional positive interim results from Purple Biotech’s Phase 2 study hold immense significance for the company. The demonstration of serum MPO as a potential predictive biomarker for overall survival benefits not only validates the efficacy of CM24 in combination therapy but also paves the way for personalized medicine in metastatic PDAC. This breakthrough could revolutionize treatment approaches, ensuring the best outcomes for patients with limited therapeutic options.
Comments